Affitech Signs Antibody Research and Licensing Agreement With Roche
Posted on: Sunday, 6 May 2007, 09:00 CDT
Affitech AS, the Norwegian human antibody therapeutics company, today announced that they have signed a research and licensing agreement with Roche to produce fully human monoclonal antibodies against an unnamed oncology target. The agreement tasks Affitech with first using their proprietary phagemid library, high throughput screening technology and antibody engineering platforms to identify candidate antibodies which Roche would then utilize for further development and commercialization. The financial terms of the collaboration include research fees, milestone payments and royalties on net sales upon commercialization of any product.
"These are exciting times for Affitech," commented Martin Welschof, Ph.D., Chief Executive Officer of Affitech. "We are delighted that Roche has chosen to partner with us based on our significant achievements to date in the human antibody field. Partnering is a key part of our twin-track strategy of generating revenue streams from collaborations parallel to developing our own therapeutic candidate pipeline. This new agreement is the latest in a series of collaborations, also in oncology that we have made with some of the other global antibody companies including the US based Xoma and Peregrine Pharmaceuticals".
Editor's notes
Affitech AS is a privately held human therapeutic antibody discovery and development company with headquarters and R&D facilities in Oslo, Norway and its US subsidiary in the San Francisco Bay Area. The Company's current disease focus is oncology and it utilizes two discrete but unique approaches for the discovery of fully human antibodies - (i) Molecule Based Antibody Discovery, and (ii) Cell Based Antibody Discovery. Molecule Based Antibody Discovery involves proprietary PhagemidScreeN and AffiScreeN™ technologies and uses validated targets for discovery purpose. Cell Based Antibody Discovery is based on CBAS™ technology, which is a "reverse-screening" approach for discovering antibodies and their cognate targets utilizing disease-specific cells. Several of the Company's proprietary product candidates currently in development were generated by CBAS™. Affitech also sells its proprietary Protein L product line for the purification of antibody and antibody fragments. Affitech offers collaborators a flexible business model and very competitive price structure with low royalty stacking. The Company has concluded deals with commercial organizations such as XOMA, NatImmune, Peregrine, Viventia, Dyax, and others. Further information at www.affitech.com.
Source: Business Wire
Related Articles
- Regeneron and Columbia University Enter Into a Strategic VelocImmune(R) Agreement to Discover Human Monoclonal Antibodies
- Morphotek(R) Announces Collaboration to Facilitate Development of Human Monoclonal Antibodies for the Treatment or Prophylaxis of Infectious Disease
- Strategic Diagnostics Inc. To Present Application Data on Proprietary Antibody Development System
- Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
- Mymetics' HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
- Dyax Corp. And Glenmark Enter Into Funded Research Agreement for Discovery of Therapeutic Antibodies
- AstraZeneca Licenses Regeneron's VelocImmune(R) Technology for Discovering Human Monoclonal Antibodies
- BioInvent Enters Collaboration With Genentech to Develop and Commercialize BioInvent's Proprietary Antibody for the Potential Treatment of Cardiovascular Diseases
- Morphotek Announces Acceptance of Investigational New Drug Application for MORAb-003, a Humanized Monoclonal Antibody for the Treatment of Advanced Ovarian Cancer
 |
 |
User Comments (0)
RSS Feeds